Pharmaceuticals, Biotechnology and Life Sciences
– Significant recent progress achieved across pipeline of innovative Bicycle®–based therapies for oncology and beyond – Dosing underway in Phase…
Revenues of $47.4 billion for the Second Quarter, a 9.5% Percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $4.64…
End of Phase 2 meeting scheduled with the U.S. Food and Drug Administration (FDA) with feedback from the meeting expected…
LONDON–(BUSINESS WIRE)–#CompetitiveIntelligence–Infiniti Research is the world’s leading independent provider of strategic market intelligence solutions. Our market intelligence services are designed…
Certara is applying expertise in clinical pharmacology, innovation and collaboration to accelerate potential prophylaxis for COVID-19.
GSK expects gross proceeds from the divestment to be £3.4 billion and net proceeds from the divestment to be £2.9 billion.
Bristol Myers Squibb has reported first quarter revenues of $10.8 Billion, an increase of 82%, on a pro forma basis, revenue increase of 13% or 8% excluding impact of COVID-19.
Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced a $390 million Series D financing round.
Ironwood has increased total revenue by 16% year-over-year to $80 million, driven primarily by U.S. LINZESS collaboration revenue of $71 million.
Atara reported net losses of $73.5 million, or $1.20 per share, for the first quarter of 2020 as compared to $66.3 million, or $1.44 per share, for the same period in 2019, with the total operating expenses include non-cash expenses of $14.5 million for the first quarter 2020, as compared to $13.9 million for the same period in 2019.